IL17A and schizophrenia: However, we observed inconsistent results in that there were significant decreases in serum levels of TNF-α, IL-1β, IFN-γ, and IL-17 after 6 weeks of treatment in first-episode drug-naïve patients with schizophrenia, while there was no change in levels of IL-4 and IL-6.